过去十年,跨国药企的研发投入几乎都指向一个方向:在新药越来越难做,单个产品的开发成本越来越高,技术平台越来越复杂的背景下,研发预算顺理成章地一路攀升。但到了2025年,风向似乎变了。开始有人猛踩油门,有人主动收手;有人把钱继续砸向后期管线和前沿技术,有人则把预算从内部研发转向BD、并购和优化自身资产配置。全球药企研发投入TOP10中的6家公司,都出现了不同规模的研投金额下滑,而这一数字在2024年...
Source Link过去十年,跨国药企的研发投入几乎都指向一个方向:在新药越来越难做,单个产品的开发成本越来越高,技术平台越来越复杂的背景下,研发预算顺理成章地一路攀升。但到了2025年,风向似乎变了。开始有人猛踩油门,有人主动收手;有人把钱继续砸向后期管线和前沿技术,有人则把预算从内部研发转向BD、并购和优化自身资产配置。全球药企研发投入TOP10中的6家公司,都出现了不同规模的研投金额下滑,而这一数字在2024年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.